Related Experiment Videos
[Undertreatment in secondary prevention of patients with coronary heart disease after revascularization]
S Silber1, I Krischke, M Prohaska
1Herzkatheterlabor, Klinik Dr. Müller, München. silber@med.de
Insights
Patients with coronary artery disease are undertreated with essential medications for secondary prevention. Adherence to guideline-recommended drugs like aspirin, statins, beta-blockers, and ACE-inhibitors is suboptimal, highlighting a critical gap in cardiovascular care.
Area of Science:
- Cardiology
- Preventive Medicine
- Pharmacology
Context:
- Coronary artery disease (CAD) remains a leading cause of mortality in developed nations.
- Effective secondary prevention strategies are crucial for managing patients with known CAD.
- Current treatment protocols emphasize lifestyle changes and optimal medical therapy for risk factor modification.
Purpose:
- To assess the adherence to evidence-based secondary prevention medications in patients with established coronary artery disease.
- To analyze prescribing patterns of aspirin, statins, beta-blockers, and ACE-inhibitors in real-world clinical practice.
- To identify gaps between recommended and actual medication use for secondary prevention of CAD.
Summary:
- Analysis of patient data and published literature reveals suboptimal prescription rates for key secondary prevention drugs, including aspirin (or clopidogrel), lipid-lowering drugs (statins), beta-blockers, and ACE-inhibitors.
- Despite guidelines recommending these medications for all eligible patients, actual uptake varies significantly, with some studies showing a decline in adherence over time.
- The concept of a fixed-dose combination pill ('secondary prevention mix') is introduced as a potential solution to improve adherence.
Impact:
- Findings suggest that patients with coronary artery disease are frequently undertreated regarding essential secondary prevention medications.
- Highlights a discrepancy between clinical guidelines and actual clinical practice, indicating a need for improved prescribing and patient adherence.
- Emphasizes the importance of optimizing medical therapy to reduce cardiovascular events and improve outcomes in CAD patients.
Abstract:
Coronary artery disease is still the no. 1 killer in the developed countries and must thus be detected and treated at an earlier stage. If coronary artery disease is advanced, patients have to be examined regarding the need for revascularization. For secondary prevention, of course, an optimal change of life style and optimal medical treatment of risk factors is mandatory. Independent of the optimal risk factor modification, all of these patients (according to the rules of evidence-based medicine) should take ASA, statins, beta blockers and ACE-inhibitors, if no contraindications or intolerance are present. Therefore, the problem in secondary prevention is not how to identify these patients, but rather how to fulfill their needs. In our own survey in patients with known coronary artery disease referred for PTCA (including patients with post myocardial infarction previous PTCA or bypass surgery), only 89% were on ASA (or clopidogrel), 51% on lipid lowering drugs (46% on statins), 65% on beta blockers, and only 43% had an ACE-inhibitor (MUNICH data in Figures 1 to 4). The analysis of published literature is also depicted in Figures 1 to 4. Until 1996, patients with known coronary artery disease took ASA in only 26% of the cases but later on it was 77 to 100% (Figure 1). Lipid lowering drugs (especially statins) are prescribed in only 13 to 77% (Figure 2), beta blockers in only 30 to 80% (Figure 3) and ACE-inhibitors in only 10 to 72% (Figure 4). In 2 major studies, a decrease in the rate of intake of these drugs during the follow-up years has been documented. The "ideal tablet" for secondary prevention contains ASA (100 mg), a statin (e.g. for most statins 40 to 80 mg), a beta blocker (e.g. metoprolol 100 mg or bisoprolol 10 mg) and an ACE-inhibitor (e.g. ramipril 10 mg). So this ideal "SPM" ("secondary prevention mix") tablet contains 160 to 300 mg of drugs. In conclusion, the analysis of published data for Europe and the USA shows that--in contrast to the statements of politicians and health care insurance companies--we are not overtreating but rather undertreating our patients regarding medications for secondary prevention.